Safety and Efficacy of Upadacitinib for Pediatric Patients with Polyarticular Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase-1 Trial

Ingrid Pan, PharmD, pediatric clinical pharmacist at Children's Hospital Colorado, reviews an interim analysis of a Phase 1 trial on the safety and efficacy of upadacitinib in pediatric patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). The study, published in Annals of the Rheumatic Diseases, shows promising results, with ACR 30, 50, and 70 response rates at week 12, and significant improvements in disease activity. Ingrid highlights the low rate of serious adverse events and discusses the potential impact of upadacitinib as an oral treatment option for pcJIA. Stay tuned for more updates on the trial.